新型P100体外冲击波治疗IIIB型慢性前列腺炎/慢性盆腔疼痛综合征的疗效:一项假治疗对照前瞻性临床试验
该随机单盲假治疗对照试验纳入83例IIIB型CP/CPPS患者,P100组51例接受每周一次低强度ESWT(0.2 mJ/mm²)共4次,对照组32例接受阻断冲击传输的相同操作。第4周临床应答率P100组78.4%显著高于对照组25%(P<0.001),NIH-CPSI中位数从基线35降至第4周13、第8周12,症状缓解持续且无反弹,未报告治疗相关不良事件。
要点
- P100 ESWT第4周临床应答率78.4%,显著高于假治疗组25%(P<0.001)。
- NIH-CPSI中位数由基线35降至第4周13、第8周12,改善持续无反弹。
- PDS、IPSS、VAS评分最早第2周显著下降(P<0.05),未见治疗相关不良事件。
核心结论
- P100 ESWT对IIIB型CP/CPPS提供快速、显著且持续的症状缓解,尤其在疼痛和排尿领域。
- 激素平衡(E2/T)可能影响ESWT后勃起功能的长期维持。
- P100可作为CP/CPPS安全有效的非侵入性治疗选择,但需更大样本和更长随访进一步验证。
研究设计与样本
- 随机、单盲、假治疗对照前瞻性临床试验,纳入83例IIIB型CP/CPPS患者。
- P100治疗组51例,接受每周一次低强度ESWT(0.2 mJ/mm²)共4次;对照组32例接受冲击传输阻断的相同操作。
- 主要终点为第4周临床应答率(NIH-CPSI评分降低≥6分),第8周进一步分析持续疗效。
- 次要终点包括IPSS、IIEF-5和VAS评分。
主要发现
- 第4周临床应答率P100组78.4%,对照组25%(P<0.001)。
- NIH-CPSI中位数从基线35降至第4周13和第8周12,提示持续改善。
- PDS、IPSS和VAS评分最早第2周显著下降(P<0.05),症状缓解稳定至第8周无反弹。
- 探索性分析提示较低基线雌二醇水平和较低E2/T比值可能与勃起功能更持续改善相关。
- 未报告治疗相关不良事件。
关键数值与推荐
- 临床应答定义为NIH-CPSI评分降低≥6分。
- ESWT方案为每周一次低强度0.2 mJ/mm²,共4次。
临床怎么用
- P100 ESWT可作为IIIB型CP/CPPS的非侵入性治疗选项,重点关注疼痛和排尿症状改善。
- 治疗前可关注雌二醇水平和E2/T比值,或有助于预判勃起功能长期维持效果。
局限性
- 样本量有限(共83例),需更大样本研究验证。
- 随访至第8周,需更长随访评估长期疗效。
- 探索性激素分析结果需进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the therapeutic efficacy and clinical applicability of the novel P100 extracorporeal shock wave therapy (ESWT) device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS: In this randomized, single-blind, sham-controlled trial, 83 patients with type IIIB CP/CPPS were enrolled and randomly assigned to either the P100 treatment group (n = 51) or the control group (n = 32). Patients in the treatment group received four weekly low-intensity ESWT sessions (0.2 mJ/mm²), while the control group received identical procedures with shock transmission blocked. The primary endpoint was the clinical response rate (≥6-point reduction in NIH-CPSI score) at week 4; week 8 outcomes were further analyzed to assess sustained efficacy. Secondary endpoints included IPSS, IIEF-5, and VAS scores. RESULTS: At week 4, the clinical response rate was 78.4% in the P100 group compared with 25% in the control group (P < 0.001). Median NIH-CPSI scores decreased from 35 at baseline to 13 at week 4 and 12 at week 8, indicating sustained improvement. Significant reductions in PDS, IPSS, and VAS scores were observed as early as week 2 (P < 0.05), and symptom relief remained stable through week 8 without rebound. Exploratory analyses suggest that lower baseline estradiol levels and lower E2/T ratios may be associated with more sustained improvements in erectile function. No treatment-related adverse events were reported. CONCLUSION: The P100 ESWT device provided rapid, significant, and sustained symptom relief for type IIIB CP/CPPS, particularly in pain and urinary domains. Hormonal balance (E2/T) may influence the long-term maintenance of erectile function after ESWT. These findings support P100 as a safe and effective non-invasive therapeutic option for CP/CPPS, warranting further validation in larger studies with longer-term follow-up.
引用
- Zhang H, Song W, Ni J, et al. Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial. Prostate Cancer Prostatic Dis. 2026. PMID: 41593221. doi:10.1038/s41391-026-01072-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。